echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BeiGene Baizean's new indications for listing application are accepted in China

    BeiGene Baizean's new indications for listing application are accepted in China

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BeiGene announced today that the NMPA Drug Evaluation Center has accepted its anti-PD-1 antibody drug Bezan for the treatment of previously treated, locally advanced unresectable or metastatic highly microsatellite unstable (MSI-H) or wrong Application for new indications for patients with solid tumors with defective repair (dMMR)
    .

    The marketing application for this new indication is based on the results of a single-arm, multi-center, open phase 2 clinical trial (NCT03736889)
    .


    The trial aims to evaluate the efficacy and safety of Baizian® monotherapy in patients with previously treated, locally advanced unresectable or metastatic MSI-H or dMMR solid tumors.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.